The results of this phase III KEYNOTE-991 study do not support the addition of pembrolizumab to enzalutamide and ADT for the treatment of mHSPC,” researchers wrote.

As of this writing, the role of PD-L1 inhibitors in prostate cancer remains limited to a subset of patients with metastatic microsatellite instability-high, mismatch repair-deficient, or tumor ...

Radium-223 in mCRPC showed long-term favorable safety, low second primary malignancies/fracture rates, and consistent overall ...

MEVPRO-2 (NCT06629779) is a global, randomized, double-blind, placebo‑controlled phase III trial in ARPI-naïve mCRPC patients. The key inclusion and exclusion criteria are detailed in the table below.

At a median follow-up of 60.7 months, patients in the combination arm of enzalutamide + leuprolide had significantly superior 5-year metastasis free survival rates (87.3% versus 71.4%; HR: 0.42, 95% ...

The FDA approved the poly ADP ribose polymerase (PARP) inhibitor in June 2023 in combination with enzalutamide for men with ...

Dr. Kristen Scarpato explains the role of genetic testing in prostate cancer care, as well as its use in determining ...

Castration-resistant prostate cancer (CRPC) remains incurable, due to resistance to therapies including the new generation of androgen receptor pathway inhibitors (ARPIs) such as enzalutamide.

prostate cancer therapy Xtandi (enzalutamide), and Inlyta (axitinib) for kidney cancer. That shift could protect the company from some of the price-cutting measures in the Inflation Reduction Act ...

treated with XTANDI™ (enzalutamide), an androgen receptor pathway inhibitor (ARPI), plus androgen depri NEW YORK, May 20, 2025--Pfizer Inc. (NYSE: PFE) today announced it has entered into an ...

Community oncology faces significant challenges from the Inflation Reduction Act's (IRA) drug pricing changes, risking ...